These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34941946)

  • 1. Inhaled ciprofloxacin-loaded poly(2-ethyl-2-oxazoline) nanoparticles from dry powder inhaler formulation for the potential treatment of lower respiratory tract infections.
    Sabuj MZR; Dargaville TR; Nissen L; Islam N
    PLoS One; 2021; 16(12):e0261720. PubMed ID: 34941946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of Inhaled Ciprofloxacin-Loaded Poly(2-ethyl-2-oxazoline) Nanoparticle Dry Powder Inhaler Formulation in High Stressed Conditions.
    Sabuj MZR; Rashid MA; Dargaville TR; Islam N
    Pharmaceuticals (Basel); 2022 Oct; 15(10):. PubMed ID: 36297335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic and Bactericidal Effects of Inhalable Ciprofloxacin-Loaded Poly(2-ethyl-2-oxazoline) Nanoparticles with Traces of Zinc Oxide.
    Sabuj MZR; Huygens F; Spann KM; Tarique AA; Dargaville TR; Will G; Wahab MA; Islam N
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of meropenem dry powder inhaler formulation for pulmonary drug delivery.
    Muneer S; Wang T; Rintoul L; Ayoko GA; Islam N; Izake EL
    Int J Pharm; 2020 Sep; 587():119684. PubMed ID: 32736016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection.
    Rashid MA; Muneer S; Mendhi J; Sabuj MZR; Alhamhoom Y; Xiao Y; Wang T; Izake EL; Islam N
    Int J Pharm; 2021 Oct; 608():121122. PubMed ID: 34560207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization.
    Rashid MA; Muneer S; Wang T; Alhamhoom Y; Rintoul L; Izake EL; Islam N
    PLoS One; 2021; 16(4):e0249683. PubMed ID: 33848310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
    Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
    Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Chemical Conjugation of l-Leucine to Chitosan on Dispersibility and Controlled Release of Drug from a Nanoparticulate Dry Powder Inhaler Formulation.
    Muhsin MD; George G; Beagley K; Ferro V; Wang H; Islam N
    Mol Pharm; 2016 May; 13(5):1455-66. PubMed ID: 26998555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment.
    Almurshedi AS; Aljunaidel HA; Alquadeib B; Aldosari BN; Alfagih IM; Almarshidy SS; Eltahir EKD; Mohamoud AZ
    Int J Nanomedicine; 2021; 16():2405-2417. PubMed ID: 33814907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotine hydrogen tartrate loaded chitosan nanoparticles: Formulation, characterization and in vitro delivery from dry powder inhaler formulation.
    Wang H; George G; Bartlett S; Gao C; Islam N
    Eur J Pharm Biopharm; 2017 Apr; 113():118-131. PubMed ID: 28088005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
    Karimi K; Katona G; Csóka I; Ambrus R
    J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of haloperidol-anchored albumin nanoparticles loaded with doxorubicin as dry powder inhaler for pulmonary delivery.
    Varshosaz J; Hassanzadeh F; Mardani A; Rostami M
    Pharm Dev Technol; 2015 Mar; 20(2):183-96. PubMed ID: 24219091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of ciprofloxacin-loaded nano-and microcomposite particles for dry powder inhaler formulations: preparation, in vitro characterisation, and antimicrobial efficacy.
    Topal GR; Devrim B; Eryilmaz M; Bozkir A
    J Microencapsul; 2018 Sep; 35(6):533-547. PubMed ID: 30213209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
    Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system.
    Alhajj N; O'Reilly NJ; Cathcart H
    Int J Pharm; 2022 Apr; 618():121657. PubMed ID: 35288220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.
    Arora S; Haghi M; Loo CY; Traini D; Young PM; Jain S
    Mol Pharm; 2015 Jun; 12(6):2001-9. PubMed ID: 25923171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and characterization of pH-sensitive nanocarrier based chitosan-g-poly(itaconic acid) for ciprofloxacin delivery for anti-bacterial application.
    Kumar B; Kumar P
    Int J Biol Macromol; 2024 May; 268(Pt 2):131604. PubMed ID: 38641270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of inhaled antibiotic liposome versus antibiotic nanoplex in controlling infection in bronchiectasis.
    Tran TT; Yu H; Vidaillac C; Lim AYH; Abisheganaden JA; Chotirmall SH; Hadinoto K
    Int J Pharm; 2019 Mar; 559():382-392. PubMed ID: 30731256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties.
    Ambrus R; Benke E; Farkas Á; Balásházy I; Szabó-Révész P
    Eur J Pharm Sci; 2018 Oct; 123():20-27. PubMed ID: 30016647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart.
    Tran TT; Vidaillac C; Yu H; Yong VFL; Roizman D; Chandrasekaran R; Lim AYH; Low TB; Tan GL; Abisheganaden JA; Koh MS; Teo J; Chotirmall SH; Hadinoto K
    Int J Pharm; 2018 Aug; 547(1-2):368-376. PubMed ID: 29886096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.